A window of opportunity study to assess the biological effects of enobosarm in oestrogen receptor positive, androgen receptor positive early breast cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2018
At a glance
- Drugs Enobosarm (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms EMERALD
- 24 Sep 2018 Planned number of patients changed from 146 to 147.
- 24 Sep 2018 Planned End Date changed from 30 Nov 2018 to 31 May 2019.
- 30 Jan 2017 New trial record